MetaCap

Connect Biopharma (CNTB) vs Cue Biopharma (CUE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cue Biopharma (CUE) has outperformed Connect Biopharma (CNTB) over the past year, losing 76.8% versus a loss of 80.6%. Over five years, CNTB leads with a -86.9% price change compared with -98.9% for CUE. Connect Biopharma is the larger company by market cap ($38.0 million vs $34.7 million), about 1.1 times the size, while Cue Biopharma is growing revenue faster (+195.7% vs -99.8%).

Cue Biopharma converts more of its revenue into profit, with a net margin of -96.9% versus -86687.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CNTB-80.59%CUE-76.75%
+122%+14%-94%
Nov 21, 20251 yearNov 20, 2026
CNTB-88.48%CUE-99.07%
+6%-49%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CNTB versus CUE key metrics
MetricCNTBCUE
Share price$0.59$4.15
Market cap$38.05M$34.69M
1-day change-6.08%-7.78%
YTD return-79.08%-54.64%
1-year return-80.59%-76.75%
5-year return-86.89%-98.92%
EPS (TTM)$-1.14$-27.80
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$64.00K$27.47M
Revenue growth (YoY)-99.75%+195.75%
Net income (latest FY)$-55.48M$-26.60M
Operating margin-90740.63%-96.67%
Net margin-86687.50%-96.85%
52-week high$3.82$45.50
52-week low$0.55$2.83
Distance from 52-week high-84.55%-90.88%
Analyst consensusstrong_buynone
Avg. price target upside+896.61%+2020.48%
Average volume3.98M567.02K
Shares outstanding64.49M8.36M
Employees6429
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Cue Biopharma is more profitable, keeping -96.9 cents of every revenue dollar as net income versus -86687.5 cents for Connect Biopharma.
  • Cue Biopharma grew revenue faster in its latest fiscal year (+195.75% vs -99.75%).

About Connect Biopharma

CNTB stock →

Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD).

Health Care · Biotechnology: Pharmaceutical Preparations · 64 employees

About Cue Biopharma

CUE stock →

Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees

CNTB vs CUE FAQ

Which is bigger, Connect Biopharma or Cue Biopharma?

Connect Biopharma (CNTB) is larger, with a market capitalization of $38.05M compared with $34.69M for Cue Biopharma (CUE).

Which stock has performed better over the past year, CNTB or CUE?

CUE returned -76.75% over the past 12 months, compared with -80.59% for CNTB (price return, excluding dividends). Past performance does not predict future results.

Are Connect Biopharma and Cue Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons